Fig. 3From: A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaProportions of patients achieving a first response (a platelet count of ≥ 50 × 109/L) during the 8-week double-blind treatment period after the first dose of the study treatment. HETROM-2.5, the dose was titrated from an initial dosage of once-daily 2.5 mg hetrombopag; HETROM-5, the dose was titrated from an initial dosage of once-daily 5 mg hetrombopagBack to article page